BMS creates strategic leadership committee

Share this article:
Lamberto Andreotti
Lamberto Andreotti

Bristol-Myers Squibb (BMS) has created an executive committee of four, which will serve as the company's “senior strategy and decision-making body,” according to a BMS statement.

Lamberto Andreotti was promoted from EVP to president, and retained his role as COO. He was also tapped as a member of the executive committee, along with Elliott Sigal, EVP, chief scientific officer and president of R&D, Jean-Marc Huet, EVP and chief financial officer, and Jim Cornelius, chairman and CEO.

Tracy Furey, a BMS spokesperson, told Bloomberg that the committee will guide development of the company's experimental drugs, pursue small biotechnology companies and strike profit-sharing deals for new products.

In addition to establishing the committee, BMS announced several other promotions and appointments:

  • Anthony Hooper to president, Americas
  • Beatrice Cazala to president, global commercialization, and president, Europe
  • John Celentano to president, emerging markets and Asia-Pacific
  • Carlo De Notaristefani to president, technical operations and global support functions
  • Giovanni Caforio to SVP, global and US oncology

In a separate announcement, BMS said it will collaborate with two Japanese companies—Nissan Chemical Industries and Teijin Pharma Limited—to develop and commercialize NTC-801, an experimental treatment for abnormal heart rhythm, or atrial fibrillation.

Under the terms of the deal, which includes an up-front payment of $40 million and potential milestone payments in the future, BMS will obtain exclusive licensing rights to the drug worldwide, except in Japan.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions